RSR13 ADMINISTERED TO PATIENTS RECEIVING CRANIAL RADIATION THERAPY

RSR13 给予接受颅脑放射治疗的患者

• 批准号: 6263628
• 负责人: JAMES RUFFER
• 金额: $ 2.51万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263628
• 关键词: clinical research; combination cancer therapy; drug screening /evaluation; glioblastoma multiforme; human subject; human therapy evaluation; neoplasm /cancer radiation therapy; oxygen; propionates

This study is designed to evaluate how well tumors respond to RSR13, an investigational drug that increases the amount of oxygen released from blood into the tissues, when given with radiation. Lack of oxygen in a tumor can reduce the effectiveness of radiation therapy; therefore, RSR13 may improve the effectiveness of radiation therapy by increasing oxygen delivery to the tumor. The safety of RSR13 will also be evaluated. The effectiveness of RSR13 in glioblastoma multiforme is not known. Radiation therapy is not experimental and is the standard treatment for glioblastoma multiforme. The RSR13 given in this study will be given with standard radiation therapy treatments. The main objective of this study is to evaluate how RSR13 affects the survival of patients with glioblastoma multiforme treated with standard radiation therapy. We will also evaluate the safety of repetitive daily intravenous doses of RSR13 that can be given with radiation therapy.

这项研究旨在评估肿瘤对 RSR13 的反应如何，RSR13 是一种研究药物，在接受放射治疗时可以增加从血液释放到组织中的氧气量。 肿瘤中缺氧会降低放射治疗的效果；因此，RSR13 可以通过增加肿瘤的氧气输送来提高放射治疗的有效性。 RSR13的安全性也将得到评估。 RSR13 在多形性胶质母细胞瘤中的有效性尚不清楚。放射治疗尚未进行实验，是多形性胶质母细胞瘤的标准治疗方法。 本研究中给予的 RSR13 将与标准放射治疗一起给予。本研究的主要目的是评估 RSR13 如何影响接受标准放射治疗的多形性胶质母细胞瘤患者的生存。 我们还将评估每日重复静脉注射 RSR13（可与放射治疗同时使用）的安全性。